Franklin DynaTech Fund - R

Historical Data - Daily Fund Prices & POP Breakpoints

Choose a Historical Date

Historical Date Selected:

None

Reset To Current

Important Legal Information

  • Most Franklin Templeton funds offer multiple share classes. Share classes are subject to different fees and expenses, which will affect their performance. In general, Class A/A1 have a maximum initial sales charge; Class C/C1 shares have a 1% contingent deferred sales charge; Class Z, Advisor Class and Class R6 shares have no sales charges nor Rule 12b-1 fees; Class R shares have no sales charges, but do have a Rule 12b-1 fee.
  • Total Returns include change in share price, assume reinvestment of all distributions, and reflect the deduction of fund expenses and applicable fees. Total Returns With Sales Charge: returns reflect the deduction of the stated sales charge. Total returns, distribution rate, and yields reflect any applicable expense reductions, without which the results for those impacted funds would have been lower.
  • For more information on any of our funds, contact your financial professional or download a prospectus. Investors should carefully consider a fund's investment goals, risks, sales charges and expenses before investing. The prospectus contains this and other information. Please read the prospectus carefully before investing or sending money.
  • Class R shares do not have sales charges and are only offered to certain eligible investors as stated in the prospectus.
  • All investments involve risks, including possible loss of principal. Stocks historically have outperformed other asset classes over the long term, but tend to fluctuate more dramatically over the short term. Investments in fast-growing industries like the technology and healthcare sectors (which have historically been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments. The fund may also invest in small- and mid-capitalization companies, which can be particularly sensitive to changing economic conditions, and their prospects for growth are less certain then those of larger, more established companies. These and other risks are described more fully in the fund's prospectus.
  • Source: FTSE. Important data provider notices and terms available at www.franklintempletondatasources.com.
  • Advisor Class, Class R, Class R6 and Class Z shares are only offered to certain eligible investors as stated in the prospectus. The fund offers multiple share classes, which are subject to different fees and expenses that will affect their performance. Please see the prospectus for details. Change the share class selection in the dropdown at the top of this page in order to see its performance details.

Footnotes

  1. Net Asset Value — The amount per share you would receive if you sold shares that day.
  2. Public Offering Price — Purchase price for each share of the fund on a given day. It includes the maximum initial sales charge, if any.

For US residents only.

Copyright ©2021 Franklin Templeton Investments. All Rights Reserved